In summary, here, we have discovered that CDKN2A loss promoted lung cancer progression and correlated with poor survival outcomes in lung cancer, and consolidated the role of CDKN2A‐MTAP signaling in the context of lung cancer, which might offer novel therapeutic and prognostic opportunities clinically against this disease. This evidence concerns the gene CDKN2A and lung carcinoma.